Entera Bio
ENTX | NASDAQ
$3.02
-$0.09 (-2.89%)
At close: Nov 16, 2026, 4:00 PM ET
$2.93
-$0.09 (-2.98%)
After-hours:
Nov 16, 2026, 7:03 PM ET
-2.89%
(1D)Rating
29.2
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #827/1021 (Top 81%)
Key Statistics
Market Data
Market Cap $525.9M
1D Range
3.00 3.12
52W Range
1.00 3.92
Valuation (TTM)
PE -17.76
PB 1.92
EV/EBITDA -23.54
Valuation (NTM)
Forward PE N/A
Forward PEG -0.10
Price Target $9.00
Cash Flow
FCF Yield 0.0%
SBC Adj. FCF Yield -0.6%
SBC Impact -5675.9%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -66.6% |
-44.1%
Dil EPS 3Y | 5Y -20.3% |
-451.0%
FCF 3Y | 5Y 76.8% |
36.4%
Returns
ROA -10.6%
ROE -38.5%
ROIC -6.7%
Financial Health
Net Cash
$265.49M
Current Ratio 128.41
Interest Coverage -6.70
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that curr...
Sector Healthcare
Industry Biotechnology
Employees 21
IPO Date Jun 28, 2018
Website www.enterabio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$9.00
Upside
+198.01%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ENTX